You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel Vitamin B6 based prodrugs of gemcitabine

    SBC: MBC Pharma, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): The long-term goal of this proposal is to develop more effective therapies for cancer, specifically pancreatic cancer. The specific focus of this proposal is to improve upon the anti-cancer activity of the drug gemcytabine. This will be accomplished by synthesizing novel conjugates of gemcytabine in a form that enables increased pathways for uptake into cancer ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Small Molecule Inhibitors of the BCL6 Oncoprotein

    SBC: LOHOCLA RESEARCH CORPORATION            Topic: NIDA

    DESCRIPTION (provided by applicant): Chronic pain syndromes affect 25-35% of populations around the world. The presence of chronic pain generates a massive toll on quality of life, workforce productivity and healthcare resource utilization. Although non-opiate medications have been introduced to treat chronic pain syndromes, many types of chronic/neuropathic pain do not respond to such medications ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Production of human MUC17 (CRD1-L-CRD2) recombinant protein in rice for the treat

    SBC: VENTRIA BIOSCIENCE            Topic: NIDDK

    DESCRIPTION (provided by applicant): Recent studies in animal models demonstrate that an endogenous human intestinal mucin fragment, termed MUC17, augments intestinal cell restitution and enhances healing of experimental colitis, potentially opening a newdoor to effective treatment of ulcerative colitis. However, expression of MUC17 in E. coli, yeast, and insect cells has met great challenges due ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Low-cost proinsulin-transferrin fusion protein in rice for treatment of diabetes

    SBC: VENTRIA BIOSCIENCE            Topic: NIDDK

    DESCRIPTION (provided by applicant): Diabetes has become a devastating epidemic worldwide. Insulin is commonly used as a treatment to help manage diabetes because of its ability to control blood glucose levels, and is in high demand worldwide, but it facesmultiple challenges including adverse metabolic side-effects, short in vivo pharmaceutical life, and high cost. Today, millions of people contin ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Quantum Dot Sensors for Superfund Priority Substances

    SBC: TDA RESEARCH, INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): The principal aim of this project is to obtain proof-of-concept for a new nanotechnology-based sensor material for rapid and sensitive fluorescence detection of polycyclic aromatic hydrocarbons (PAHs) and polychloro biphenyls (PCBs). Simple, cheap and safe methods to detect and quantify these toxic substances, which rank high in the ATSDR Substance Priority Lis ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Realistic Accurate Dosimulation (RAD)

    SBC: ENVIROFIT INTERNATIONAL, LLC            Topic: NIEHS

    DESCRIPTION (provided by applicant): The ambient concentration of airborne pollutants such as CO and PM2.5 particulates in rural homes of developing countries such as Kenya has been observed to exceed World Health Organization (WHO) exposure limits up to 30X, and US Environmental Protection Agency limits by 100X. This indoor air pollution (IAP) has been linked to nearly 3% of the global burden of ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Micro Patterned Intraocular Lens Membrane for Reducing Incidence of PCO

    SBC: Sharklet Technologies Inc.            Topic: NEI

    DESCRIPTION (provided by applicant): The exponential increase of diabetics and the elderly in the U.S. has at least tripled cataract surgeries in just two decades. As many as half of these surgeries will lead to posterior capsular opacification (PCO), which requires follow-up surgery using Nd:YAG laser capsulotomy. Without this additional surgery, patients can suffer permanent vision loss. In many ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase

    SBC: ABLELINK TECHNOLOGIES INC            Topic: NICHD

    DESCRIPTION (provided by applicant): For most Americans, understanding and planning a healthy daily menu can be a confusing and multi- faceted process. The cognitive challenges faced by people with intellectual disabilities (ID) create even greater barriers in understanding the complexity of nutritional concepts such as the food groups, caloric values, saturated fats, cholesterol, daily recommende ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Use Mobile Devices and Cloud Computing Platforms for Real-time Data Solutions in

    SBC: INVENUX, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a botanical drug for use in children that prevents theinexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. An Automated Platform for High-throughput Network Electrophysiology

    SBC: CALISTA THERAPEUTICS INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Calista Therapeutics has discovered a first-in-class, proprietary PDZ1-2 lead drug, AT010, that is being optimized and developed as an inhaled daily therapy for cystic fibrosis (CF). CF is a deadly inherited genetic disorder that disrupts chloride channel function, resulting in the buildup of sticky mucus in patient's lungs and other organs.CF patients hav ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government